EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients



Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients



Blood 94(10): 3315-3324



Fifty-eight acute promyelocytic leukemia (APL) patients (11 newly diagnosed and 47 relapsed) were studied for arsenic trioxide (As2O3) treatment. Clinical complete remission (CR) was obtained in 8 of 11 (72.7%) newly diagnosed cases. However, As2O3 treatment resulted in hepatic toxicity in 7 cases including 2 deaths, in contrast to the mild liver dysfunction in one third of the relapsed patients. Forty of forty-seven (85.1%) relapsed patients achieved CR. Two of three nonresponders showed clonal evolution at relapse, with disappearance of t(15;17) and PML-RARalpha fusion gene in 1 and shift to a dominant AML-1-ETO population in another, suggesting a correlation between PML-RARalpha expression and therapeutic response. In a follow-up of 33 relapsed cases over 7 to 48 months, the estimated disease-free survival (DFS) rates for 1 and 2 years were 63.6% and 41.6%, respectively, and the actual median DFS was 17 months. Patients with white blood cell (WBC) count below 10 x 10(9)/L at relapse had better survival than those with WBC count over 10 x 10(9)/L (P =.038). The duration of As2O3-induced CR was related to postremission therapy, because there was only 2 of 11 relapses in patients treated with As2O3 combined with chemotherapy, compared with 12 of 18 relapses with As2O3 alone (P =.01). Reverse transcription polymerase chain reaction (RT-PCR) analysis in both newly diagnosed and relapsed groups showed long-term use of As2O3 could lead to a molecular remission in some patients. We thus recommend that ATRA be used as first choice for remission induction in newly diagnosed APL cases, whereas As2O3 can be either used as a rescue for relapsed cases or included into multidrug consolidation/maintenance clinical trials.

(PDF emailed within 1 workday: $29.90)

Accession: 011415789

Download citation: RISBibTeXText

PMID: 10552940



Related references

Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia. Haematologica 89(10): 1266-1267, 2004

Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematologica 121(1): 1-8, 2009

Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. Plos One 10(3): E0121912-E0121912, 2016

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Journal of Clinical Oncology 28(24): 3866-3871, 2010

Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3 ) combination therapy in newly diagnosed acute promyelocytic leukemia (APL). Journal of Clinical Oncology 24(18_suppl): 6503-6503, 2016

Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia. Japanese Journal of Clinical Hematology 46(11): 1223-1225, 2006

Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia. Blood 98(11 Part 2): 216b, November 16, 2001

Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia. Pediatric Hematology and Oncology 29(2): 170-172, 2013

Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. Pediatric Blood & Cancer 50(4): 872-874, 2007

Treatment of children with newly diagnosed acute promyelocytic leukemia using intravenous arsenic trioxide. Blood 102(11): 620a, November 16, 2003

Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 119(1): 115-125, 2013

Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Leukemia & Lymphoma 54(9): 2041-2046, 2014

Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. American Journal of Hematology 70(4): 292-299, 2002

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 115(9): 1697-1702, 2010

Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. International Journal of Hematology 93(2): 199-205, 2011